Visceral Fat & Diabetes Disparities in the UK

Visceral fat diabetes disparities affect communities across the UK unequally, with South Asian, Black African, Black Caribbean, and Chinese populations facing significantly higher risks of type 2 diabetes at lower body weights than white European reference ranges suggest. Visceral fat, stored deep within the abdominal cavity, drives insulin resistance through inflammatory pathways that BMI alone fails to capture. Understanding why these disparities exist, how NHS screening thresholds are adjusted for different ethnic groups, and what practical steps can reduce visceral fat is essential for clinicians, patients, and anyone concerned about their long-term metabolic health.

Why does visceral fat raise your risk of type 2 diabetes?

Visceral fat raises type 2 diabetes risk by releasing inflammatory cytokines and free fatty acids into the portal circulation, impairing insulin signalling in the liver and skeletal muscle and promoting chronic insulin resistance. It is a stronger predictor of diabetes risk than BMI alone.

Visceral fat raises your risk of type 2 diabetes primarily by driving insulin resistance, a state in which the body's cells respond poorly to insulin and blood glucose rises as a result. Unlike subcutaneous fat, which sits just beneath the skin, visceral fat accumulates deep within the abdominal cavity, surrounding organs such as the liver, pancreas and intestines. This location is clinically significant because visceral fat is metabolically active: it releases free fatty acids and pro-inflammatory cytokines, including tumour necrosis factor-alpha and interleukin-6, directly into the portal circulation.^[3]

These substances impair insulin signalling in the liver and skeletal muscle, reduce the uptake of glucose from the bloodstream, and promote chronic low-grade inflammation. Over time, the pancreatic beta cells that produce insulin become exhausted trying to compensate, and blood glucose control deteriorates further. Evidence from large cohort studies and meta-analyses consistently indicates that visceral fat is a stronger predictor of type 2 diabetes risk than overall body weight or body mass index (BMI) alone.^[3][2]

Importantly, a person can carry a clinically significant burden of visceral fat while having a BMI that falls within the so-called normal range. This phenomenon, sometimes described as metabolically obese normal weight, means that BMI-based screening alone may miss individuals at genuine risk. Waist circumference and waist-to-hip ratio are therefore useful complementary measures. NICE guidance (PH46) on BMI and minority ethnic groups, and NICE guidance on obesity identification and management, both acknowledge the limitations of BMI as a sole screening tool, and these measures are best understood as risk stratification aids rather than diagnostic tests in their own right.^[1][4]

Which ethnic groups in the UK are most affected by visceral fat and diabetes?

South Asian adults in the UK are most affected, with type 2 diabetes prevalence two to four times higher than in white British populations and onset around a decade earlier. Black African, Black Caribbean, and Chinese populations also face elevated risk at lower BMI values.

People of South Asian, Black African, Black Caribbean, and Chinese heritage living in the UK are disproportionately affected by visceral fat accumulation and type 2 diabetes compared with white European populations. NHS data and reports from the Office for Health Inequalities and Disparities (OHID) and NHS England have consistently shown that South Asian adults develop type 2 diabetes at younger ages, at lower BMI thresholds, and with higher rates of visceral adiposity relative to total body fat. Prevalence of type 2 diabetes among South Asian communities in the UK is estimated to be two to four times higher than in white British populations, and onset typically occurs around a decade earlier, based on Health Survey for England data and NHS England ethnicity and diabetes analyses.^[17][18]

Black African and Black Caribbean adults also face elevated diabetes risk, though the pattern of fat distribution differs somewhat: this group tends to carry more subcutaneous fat but can still accumulate harmful levels of visceral fat, particularly in the context of dietary and lifestyle factors. Chinese and other East Asian populations similarly show higher metabolic risk at lower BMI values than white European reference ranges would suggest.

These disparities are not explained by genetics alone. Socioeconomic factors, dietary patterns, physical activity levels, and the physiological effects of chronic stress all contribute. However, there is a genuine biological component: body composition studies using imaging techniques such as MRI and DEXA scanning, including analyses from the UK Biobank MRI substudy, have demonstrated that, at equivalent BMI values, South Asian adults carry significantly more visceral fat than white European adults. This has direct implications for how screening thresholds should be applied across different ethnic groups in UK clinical practice.

How do NHS screening thresholds account for differences in body fat distribution?

NICE (PH46) recommends lower BMI thresholds of 23 kg/m² and 27.5 kg/m² for South Asian and Chinese populations, and reduced waist circumference thresholds, to reflect higher metabolic risk at lower levels of overall adiposity in these groups.

NHS and NICE guidance recommends lower waist circumference and BMI thresholds for people of South Asian, Chinese, and other high-risk ethnic backgrounds to account for the fact that metabolic risk occurs at lower levels of overall adiposity in these groups. For white European adults, a BMI of 25 kg/m² or above is used to define overweight, and 30 kg/m² or above defines obesity. For South Asian, Chinese, and other at-risk ethnic groups, NICE (PH46) recommends using a lower threshold of 23 kg/m² to define increased risk and 27.5 kg/m² to define high risk, in line with World Health Organization guidance on Asian populations.

Waist circumference thresholds are also adjusted. For South Asian men, a waist circumference of 90 cm or above is considered high risk, compared with 94 cm for white European men.^[1][3] For South Asian women, the threshold is 80 cm, the same as for white European women, though some clinical guidance recommends applying this threshold more cautiously given the evidence of greater visceral fat burden at equivalent measurements. Waist circumference should be measured at the midpoint between the lower rib and the top of the hip bone, with the tape horizontal and snug but not compressing the skin.

The NHS Diabetes Prevention Programme (NHS DPP) accepts referrals primarily on the basis of non-diabetic hyperglycaemia, defined as an HbA1c of 42 to 47 mmol/mol or a fasting plasma glucose of 5.5 to 6.9 mmol/L, and validated risk scores that incorporate ethnicity as a factor. The NHS Health Check, offered to adults aged 40 to 74 in England, is intended to identify those at elevated cardiometabolic risk and should apply ethnicity-adjusted thresholds at the point of assessment.^[7] Ensuring consistent application of these thresholds across services remains an ongoing challenge for Integrated Care Boards (ICBs) and primary care teams.

Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, alongside NHS and community-based pathways.

What health inequalities drive higher visceral fat levels in some communities?

Socioeconomic deprivation, limited access to healthy food, chronic psychosocial stress, and disrupted sleep from shift work all drive higher visceral fat levels, with sustained cortisol elevation creating a direct biological pathway from social adversity to metabolic disease.

Higher visceral fat levels in certain communities are driven by a combination of socioeconomic deprivation, food environment, chronic psychosocial stress, and structural barriers to physical activity, rather than by individual lifestyle choices alone. People living in areas of high deprivation are more likely to have limited access to affordable fresh food, to live in environments with fewer safe spaces for exercise, and to work in roles involving shift patterns or sedentary conditions that disrupt sleep and circadian rhythms. Research published in journals including Sleep and Occupational and Environmental Medicine has linked disrupted sleep and shift work to increased visceral fat accumulation and insulin resistance.

Chronic psychosocial stress, including the effects of racism, discrimination, and socioeconomic insecurity, activates the hypothalamic-pituitary-adrenal axis and raises cortisol levels. Sustained cortisol elevation promotes preferential deposition of fat in the visceral compartment, creating a direct biological pathway from social adversity to metabolic disease, as described in peer-reviewed literature on stress and adiposity. This mechanism helps explain why health inequalities in diabetes risk persist even after adjusting for diet and physical activity.

Dietary patterns also play a role. Some traditional diets within South Asian, African, and Caribbean communities are high in refined carbohydrates and saturated fats, though it is important to note that acculturation, food poverty, and the availability of culturally appropriate healthy foods all shape what people actually eat. Systematic reviews, including Cochrane analyses of culturally adapted diabetes prevention programmes, indicate that culturally sensitive dietary advice, delivered in community languages and through trusted community organisations, is more effective than generic guidance. NHS England's Core20PLUS5 framework explicitly identifies ethnic minority communities as a priority group for reducing health inequalities, including those related to diabetes and cardiovascular disease.

How can you reduce visceral fat and lower your diabetes risk in the UK?

Reducing ultra-processed foods and refined carbohydrates, achieving at least 150 minutes of moderate aerobic activity weekly, and improving sleep can meaningfully reduce visceral fat. MHRA-authorised medicines such as tirzepatide may be considered where clinically appropriate under NICE guidance.

Visceral fat can be meaningfully reduced through a combination of dietary change, increased physical activity, improved sleep, and, where clinically appropriate, pharmacological support. Unlike subcutaneous fat, visceral fat responds relatively quickly to lifestyle intervention: studies show that even a modest reduction in total body weight of 5 to 10 per cent can produce significant decreases in visceral fat volume and measurable improvements in insulin sensitivity, as reflected in NICE obesity guidance.^[2][19]

From a dietary perspective, reducing intake of ultra-processed foods, refined carbohydrates, and sugar-sweetened beverages has the strongest evidence base for reducing visceral adiposity. A Mediterranean-style dietary pattern, rich in vegetables, legumes, wholegrains, oily fish, and unsaturated fats, is supported by NICE and NHS guidance for both weight management and diabetes prevention. Culturally adapted versions of this approach, developed with input from community dietitians, are more likely to be sustainable for people from South Asian, African, and Caribbean backgrounds.

Physical activity guidance from the UK Chief Medical Officers' Physical Activity Guidelines recommends at least 150 minutes of moderate-intensity aerobic activity per week for adults, alongside muscle-strengthening activities on two or more days.^[8][9] Both aerobic exercise and resistance training independently reduce visceral fat, and combining the two produces greater benefit than either alone.

For people who meet clinical criteria, pharmacological treatment may be considered under NICE guidance and local ICB commissioning pathways. Medicines such as semaglutide (Wegovy, available in doses up to 2.4 mg and 7.2 mg weekly) and tirzepatide (Mounjaro), which is MHRA-authorised for both type 2 diabetes and chronic weight management, have demonstrated significant reductions in visceral fat in clinical trials including MRI substudies such as SURPASS-3 and STEP imaging analyses.^[10][11] These medicines are prescribed only where clinically appropriate following assessment. Referral to the NHS Diabetes Prevention Programme is available through a GP for those with an HbA1c of 42 to 47 mmol/mol or a fasting plasma glucose of 5.5 to 6.9 mmol/L.

If you experience symptoms that may suggest high blood glucose, such as increased thirst, frequent urination, or unexplained weight loss, speak to your GP promptly. People with diabetes who develop symptoms such as acute abdominal pain, vomiting, or rapid deep breathing should seek urgent medical assessment, as these may indicate diabetic ketoacidosis (DKA). If you experience a suspected side effect from any medicine, you can report it to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Frequently Asked Questions